Cenix Bioscience said last week that it has joined a European Union-funded consortium focused on improving the in vivo use of siRNAs for respiratory and inflammatory diseases.
According to the company, it joined the consortium after one-time member Novosom dropped out following the sale of its liposome-based delivery technology to Marina Biotech last year (GSN 7/29/2010).
Cenix said that its specific contributions to the consortium will include its so-called DARE delivery technology, which it began developing in early 2008 as part of an initiative to expand beyond its core focus of high-throughput, high-content RNAi experiments in culture (GSN 4/30/2009).